Minerva Neurosciences

Biogen adds management to hemophilia spin-off Bioverativ

Monday, November 21, 2016

Biogen has announced the addition of two members to the executive management team of Bioverativ, Biogen’s planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017.

[Read More]

Minerva’s MIN-101 trial met primary endpoint in schizophrenia

Wednesday, June 1, 2016

Minerva Neurosciences has announced positive top line results from a prospective phase IIb, 12-week, randomized, double-blind, placebo-controlled parallel clinical trial evaluating the efficacy, safety and tolerability of MIN-101 in patients with negative symptoms of schizophrenia. These negative symptoms, for which no approved treatment is currently available, affect the majority of schizophrenic patients and can persist over their lifetimes.

[Read More]

Minerva completes enrollment in MIN-101 phase IIb trial

Monday, January 4, 2016

Minerva Neurosciences, a Waltham, Mass.-based clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, has announced that the FDA has accepted the company’s Investigational New Drug (IND) application for MIN-101, a first-in-class 5-HT2a and sigma2 antagonist in clinical development for the treatment of schizophrenia.

[Read More]

Minerva Neurosciences expands executive team

Thursday, March 6, 2014

Minerva Neurosciences, a developer of new therapies to treat neuropsychiatric diseases and disorders, has launched the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Mass. The establishment of a new corporate headquarters follows the recent appointment of Rogerio Vivaldi, M.D., MBA, as the new president and CEO, and Marc Beer as the new chairman of the board of directors of Minerva Neurosciences. The company was founded in 2013 by the merger of Cyrenaic Pharmaceuticals and Sonkei Pharmaceuticals.

[Read More]